Earnings Call Summary | Apyx Medical(APYX.US) Q4 2023 Earnings Conference
Earnings Call Summary | Apyx Medical(APYX.US) Q4 2023 Earnings Conference
The following is a summary of the Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript:
以下是Apyx醫療公司（APYX）2023年第四季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Apyx Medical Corporation reported a 16% year-over-year increase in total revenue to $14.7 million in Q4 2023.
The company's gross profit for Q4 2023 stood at $8.9 million, at a 60.9% gross margin.
Advanced Energy equipment sales rose by 15% year-over-year to $12.1 million, contributing significantly to total revenue.
However, an increase in operating expenses of 4% led to a net loss increase of 59% to $9.6 million.
The company's gross margins declined slightly due to year-end inventory cleanup and changes in product and customer mix.
For 2024, Apyx expects total revenue to range between $49.7 million and $52.9 million with a projected gross margin of 61%.
Apyx Medical Corporation報告稱，2023年第四季度的總收入同比增長16％，達到1,470萬美元。
該公司2023年第四季度的毛利潤爲890萬美元，毛利率爲60.9％。
先進能源設備的銷售額同比增長15％，達到1,210萬美元，爲總收入做出了重大貢獻。
但是，運營費用增長了4％，導致淨虧損增長了59％，達到960萬美元。
由於年終庫存清理以及產品和客戶結構的變化，該公司的毛利率略有下降。
Apyx預計，2024年的總收入將在4,970萬美元至5,290萬美元之間，預計毛利率爲61％。
Business Progress:
業務進展：
Apyx successfully launched the Renuvion Micro Handpiece, which received positive initial feedback.
Sales of handpieces showed strong growth within the U.S, up by over 35% year-over-year.
Internationally, Apyx reported a robust increase in generator sales by over 80% year-over-year.
In 2023, Apyx achieved its focus areas of securing additional clinical use indications, enhancing the portfolio, expanding clinical evidence, and managing expenses for profitability.
In 2024, the company aims to secure new customer adoption, particularly by simplifying the capital purchasing process.
The recently launched Micro Handpiece and Apyx One technology are key to the company's growth strategy, with emphasis on handpiece growth in 2024 and beyond.
The company continues international expansion efforts, including securing clearances in large cosmetic markets like Korea and China. It also aims to foster customer awareness through direct-to-consumer initiatives.
Apyx成功推出了Renuvion Micro Handpiece，該手機獲得了積極的初步反饋。
手機在美國境內的銷售顯示出強勁的增長，同比增長35％以上。
在國際上，Apyx報告稱，發電機銷售額同比強勁增長80％以上。
2023 年，Apyx 實現了其重點領域，即確保更多臨床用途適應症、增強產品組合、擴大臨床證據、管理費用以實現盈利。
2024年，該公司的目標是確保新客戶的採用，特別是通過簡化資本購買流程。
最近推出的微型手機和Apyx One技術是公司增長戰略的關鍵，重點是2024年及以後的手機增長。
該公司繼續努力進行國際擴張，包括確保韓國和中國等大型化妝品市場的許可。它還旨在通過直接面向消費者的舉措提高客戶意識。
More details: Apyx Medical IR
更多詳情： Apyx 醫用紅外線
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。